DOCSLIB.ORG

W LIVERPOOL Synthesis and Structure-Metabolism Relationships

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
W LIVERPOOL Synthesis and Structure-Metabolism Relationships W LIVERPOOL Synthesis and Structure-Metabolism Relationships of Halogenated Carbamazepine Analogues Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy By Emma-Claire Elliott 30th September 2011 Acknowledgem en ts I would like to begin by thanking my supervisors, Dr, Andrew V. Stachulski and Prof. B. Kevin Park, for giving me the opportunity to study with them. I am also indebted to Prof. Rick Cosstick for all his assistance, support, and encouragement in the final years of the PhD. I also express gratitude to Dr. Sophie L. Regan and Dr. James L. Maggs of the MRC Centre for Drug Safety Science for their close collaboration with the structure-metabolism work, and for their assistance in determining the purity of the carbamazepine analogues. Thanks go to the members of the Stachulski group, both past and present, and to the members of the Aspinall and Greeves group for their excellent company in the lab and for making Liverpool a thoroughly enjoyable place to work for the past for years. Special thanks go to Laura, Helen, Xiao Li, and Chandra for all their help, friendly discussions and camaraderie To all my friends, old and new, in no particular order: Jacqui, Ev, Oliver, Matt, Neil, Lyndsey, Ste, Robin and Michelle for always being on hand with a cup of tea or a pint on a Friday night. I am extremely thankful to my family, to whom I dedicate this thesis. My parents Alex and Jean, and my brother Adam, for not disowning me. For their love, support, inspiration and encouragement through good times and bad. Finally I thank Tom for always going the extra mile and especially for his forbearance over the late nights, early starts, and long weekends. Funding from the EPSRC is also gratefully acknowledged. i Abstract Adverse drug reactions are a significant burden on industry and healthcare providers. They account for approximately 5 % of hospital admissions and are a considerable cause of morbidity and mortality in patients. While it is widely considered that an individual's susceptibility to idiosyncratic reactions is caused by a variety of factors; ADRs are thought to be linked to the formation and accumulation of reactive drug metabolites rather than the parent drug. Of the patients administered carbamazepine 30-50 % are subject to the development of some form of adverse drug reaction. Carbamazepine is metabolized extensively in vivo and hypersensitivity reactions have been hypothetically linked to the formation of chemically reactive arene oxide or iminoquinone metabolites. In order to understand the mechanisms behind such ADRs it is important to synthesize a variety of chemical probes to observe changes in pharmacokinetic and pharmacodynamic properties of the compounds. The overall theme of this thesis is the synthesis and the examination of the structure-metabolism relationships for halogenated analogues of carbamazepine, It is divided into three main sections; a general introduction introduces the reader to the basics of drug metabolism from how drugs are metabolized to the implications of halogen substitution on the metabolism of drugs. It next covers the synthetic strategies employed in the formation of halogenated carbamazepine analogues before ending on a discussion of the key findings of the structure-metabolism relationships that may be derived from in vitro investigations 11 Publications Elliott, E.-C.; Bowkett, E. R.; Maggs, J. L.; Bacsa, J.; Park, B. K,; Regan, S. L; O'Neill, P. M.; Stachulski, A. V., Convenient Syntheses of Benzo-Fluorinated Dibenz[b,f]azepines: Rearrangements of Isatins, Acridines, and Indoles. Organic Letters 2011. Paper in press Emma-Claire Elliott, Sophie L. Regan, James L. Maggs, Elizabeth R. Bowkett, Laura Parry, Dominic P. Williams, B. Kevin Park, and Andrew V. Stachulski: Haloarene derivatives of carbamazepine with reduced bioactivation liabilities: 2-monohalo and 2,8-dihalo derivatives. Manuscript in Preparation Abbreviations 9-AC 9-Acridine carbaldehyde ABT 1-Aminobenzotriazole AC2O Acetic anhydride ACBN l,r-Azobis[cyclohexanecarbonitrile) AcCl Acetyl chloride Acetone-dfi Deuterated acetone ADR Adverse Drug Reaction AI Acridine AO Acridone ATR-IR Attenuated Total Reflection Infrared Spectroscopy br. s. Broad singlet CBZ Carbamazepine CBZ-2,8-Br 2,8-DiBromo carbamazepine CBZ-2,8-Br E 2,8-DiBromo carbamazepine-10,11-epoxide CBZ-2,8-Br -A-gluc 2,8-DiBromo carbamazepine-iV-glucuronide CBZ-2,8-BrE-A-gluc 2.8-DiBromo carbamazepine-10,11-epoxide-IV-glucuronide CBZ-2,8-Cl 2.8-DiChloro carbamazepine CBZ-2,8-Cl E 2,8-DiChloro carbamazepine-10,11-epoxide CBZ-2,8-Cl E-A-gluc 2,8-DiChloro carbamazepine-10,11-epoxide-N-glucuronide CBZ-2,8-Cl -JV-gluc 2.8- DiChloro carbamazepine-iV-glucuronide CBZ-2.8-F 2.8- DiFluoro carbamazepine CBZ-2,8-F -iV-gluc 2,8-DiFluoro carbamazepine-Af-glucuronide CBZ-2.8-FE 2,8-DiFluoro carbamazepine-10,11-epoxide CBZ-2,8-FE-JV-gluc 2,8-DiFluoro carbamazepine-10(ll-epoxide-lV-glucuronide CBZ-2-Br 2-Bromo carbamazepine CBZ-2-BrE 2-Bromo carbamazepine-10,11-epoxide CBZ-2BrE-A-gluc 2-Bromo carbamazepine-10,11-epoxide-Af-glucuronide CBZ-2-Br-JV-gluc 2-Bromo carbamazepine-iV-glucuronide CBZ-2-C1 2-Chloro carbamazepine CBZ-2-C1E 2-Chloro carbamazepine-10,11-epoxide CBZ-2-ClE-iV-gluc 2 -Chloro carbamazepine-10,1 l-epoxide-N-glucuronide CBZ-2-Cl-iV-gluc 2-Chloro carbamazepine-Af-glucuronide CBZ-2-F 2-Fluoro carbamazepine CBZ-2-F E 2-Fluoro carbamazepine-10,11-epoxide CBZ-2-F E-iV-gluc 2-Fluoro carbamazepine-10,11-epoxide-Af-glucuronide iv CBZ-2-F -W-gluc 2-Fluoro carbaraazepine-W-glucuronide CBZ-2-F.OSO3 2-Fluoro carabamazepine O-sulfonate CBZ-2-0H 2-Hydroxy carbamazepine CBZ-3-0H 3-Hydroxy carbamazepine CBZDHD Carbamazepine-10,ll-dihydrodiol CBZE Carbamazepine-10,11-epoxide CBZ-JV-Gluc Carbamazepine-N-glucuronide CBZ-SG Carbamazepine-glutathione conjugate CC14 Carbon tetrachloride CDCIs Deuterated chloroform CF3SO3H Trifluromethyl sulfonic acid CH2CI2 Dichloromethane (methylene chloride) CHCls Chloroform Cl Chemical Ionisation d Doublet dd Doublet of doublets ddd Doublet of doublets of doublets DHD Di-hydrodiol DHOH Dihydroxylated DMAP Dimethyl amino pyridine DMSO Dimethylsulfoxide DMSO-f/g Deuterated dimethylsulfoxide dt Doublet of triplets El Electron Ionisation eq Equivalents Et20 Diethyl ether EtOAc Ethyl acetate EtOH Ethanol GSH Glutathione GST Glutathione-S-transferase h Hours HBr Hydrogen bromide HC1 Hydrochloric Acid HLM Human Liver Microsomes HPLC High-Pressure Liquid Chromatography I2 Iodine V IDB Iminodibenzyl IR Infra-Red spectroscopy ISB Iminostilbene ISB-2-0H 2-Hydroxy iminostilbene K2CO3 Potassium carbonate KOCN Potassium isocyanate KOH Potassium Hydroxide LC-MS High Pressure Liquid Chromatography-Mass Spectrometry LC-UV High Pressure Liquid Chromatography (with UV detection) m (NMR) multiplet; (IR) medium MeCN Acetonitrile min Minutes mp Melting Point MPO Myeloperoxidase Na2S04 Sodium sulfate NaOCN Sodium isocyanate NaOH Sodium Hydroxide NAPQI IV-acetyl para-benzo quinoneimine NBS N-bromo succinimide NCS IV-chloro succinimide NEt3 Triethylamine NH4CI Ammonium chloride NIH National Institutes of Health NMR Nuclear Magnetic Resonance P450 Cytochrome P450 PEG 400 Polyethylene glycol (molecular weight = 400) PI1CF3 Trifluoromethyl toluene pKa acid dissociation constant PPA Polyphosphoric acid P£-Bu3 Tri-tert-butyl phosphine q Quartet s (NMR) singlet (IR) strong SAR Structure-Activity Relationship Si02 Silica Gel SKF Proadifen hydrochloride t Triplet VI TFA Trifluoroacetic acid THF Tetrahydro furan TIC Total Ion Current TLC Thin layer chromatography w Weak w/v Weight to volume WHO World Health Organisation XIC Extracted Ion Current Structural Abbreviations Abbreviation Structure CBZ-2-OH CBZ-3-OH AI AO CBZ CBZE CBZE-JV-gluc OH OH vm CBZ-W-gluc Glucuronic acid GSH (glutathione] ix Contents Acknowledgements i Abstract ii Publications iii Abbreviations iv Structural Abbreviations viii Contents x 1. General Introduction 2 1.1 Drug metabolism 2 1.1.1 Cytochrome P450 and oxidative metabolism 5 1.1.2 Cytochrome P450 Catalytic cycle 6 1.1.3 Other forms of oxidative metabolism 9 1.2 Carbamazepine 13 1.2.1 Carbamazepine Metabolism 14 1.3 Implications of Halogen Substitution 20 1.3.1 Physicochemical properties of Carbon-Halogen bonds 20 1.3.2 Metabolic dehalogenation 27 1.3.3 Halogens and the National Institutes of Health (NIH) shift 31 1.4 Conclusions 35 1.5 References 37 2. Synthesis of Halogenated Carbamazepine Derivatives 48 2.1. Introduction: Dibenz[/E>,/|azepines and related ring systems 48 2.2 Synthesis of dibenzfh/Jazepines by ring closing reactions 50 2.3 Synthesis of dibenz[hj]azepines by ring expansion reactions 56 2.4 Synthetic project aims 61 2.5 Direct Electrophilic Halogenation of Iminodibenzyl 62 2.5.1 Direct electrophilic bromination with N-halo succinimides 62 2.5.2 Incorporation of the 10,11-double bond 69 2.5.3 Radical Bromination of the 10-11 bond 72 2.6 Synthesis from Halogenated Building Blocks 80 2.6.1 Synthesis of N-aryl Indoles 80 2.6.2 Polyphosphoric acid cyclisation 88 2.7 Incorporation of the carboxamide moiety 96 2.7.1 Phosgenation 96 x 2.7.2 Isocyanates 100 2.8 Conclusions 108 2.9 References 109 3. Results and Discussion: Structure-Metabolism Relationships of Halogenated Carbamazepine Analogues 117 3.1 Introduction 117 3.2 Project Aims 118 3.3 Identification of CBZ Metabolites in freshly isolated hepatocyte suspensions 119 3.3.1 Rat vs. Mouse metabolism 119 3.3.2 Role of Cytochromes P450 in CBZ metabolism in hepatocyte suspensions 127 3.3.3 Structure-metabolism relationships
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Of 36 Commentary USP 40–NF 35, First Supplement February 1, 2017
    Commentary USP 40–NF 35, First Supplement February 1, 2017 In accordance with USP’s Rules and Procedures of the Council of Experts (“Rules”) and except as provided in Section 7.02 Accelerated Revision Processes, USP publishes proposed revisions to the United States Pharmacopeia and the National Formulary (USP–NF) for public review and comment in the Pharmacopeial Forum (PF), USP’s free bimonthly journal for public notice and comment. After comments are considered and incorporated as the Expert Committee deems appropriate, the proposal may advance to official status or be re-published in PF for further notice and comment, in accordance with the Rules. In cases when proposals advance to official status without re-publication in PF, a summary of comments received and the appropriate Expert Committee's responses are published in the Revisions and Commentary section of the USP.org at the time the official revision is published. The Commentary is not part of the official text and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis of Expert Committees’ responses to public comments on proposed revisions. If there is a difference between the contents of the Commentary and the official text, the official text prevails. In case of a dispute or question of interpretation, the language of the official text, alone and independent of the Commentary, shall prevail. For further information, contact: USP Executive Secretariat United States Pharmacopeia 12601 Twinbrook Parkway Rockville, MD 20852-1790 USA [email protected]
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Deferrals for USP39-NF34 2S
    Compendial Deferrals for USP39-NF34 2S Category Monograph Title Monograph Section Scientific Liaison Title, Introduction, DEFINITION/Introduction, IDENTIFICATION/A., IDENTIFICATION/B., ASSAY/Procedure, PURITY/Procedure, IMPURITIES/Clostripain Activity/Potassium phosphate buffer, IMPURITIES/Clostripain Activity/Dithiothreitol solution, IMPURITIES/Clostripain Activity/Calcium chloride solution, IMPURITIES/Clostripain Activity/Substrate stock solution, IMPURITIES/Clostripain Activity/Substrate solution, IMPURITIES/Clostripain Activity/Sample solution, IMPURITIES/Clostripain Activity/Instrumental conditions, IMPURITIES/Clostripain Activity/Analysis, IMPURITIES/Clostripain Activity/System suitability, IMPURITIES/Clostripain Activity/Acceptance criteria, IMPURITIES/Trypsin Activity/Buffer, IMPURITIES/Trypsin Activity/Substrate stock solution, IMPURITIES/Trypsin Activity/Substrate solution, IMPURITIES/Trypsin Activity/Sample solution, IMPURITIES/Trypsin Activity/Instrumental conditions, IMPURITIES/Trypsin Activity/Analysis, IMPURITIES/Trypsin Activity/System suitability, IMPURITIES/Trypsin Activity/Acceptance criteria, SPECIFIC TESTS/Protein Content, SPECIFIC TESTS/Bacterial Endotoxins Test <85>, SPECIFIC TESTS/Microbial Enumeration Tests <61>, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling, ADDITIONAL REQUIREMENTS/USP New <89.1> COLLAGENASE I PF 41(5) Pg. ONLINE Reference Standards <11> Edith Chang Title, Introduction, DEFINITION/Introduction, IDENTIFICATION/A., IDENTIFICATION/B., ASSAY/Procedure, PURITY/Procedure,
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • WO 2007/061529 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 31 May 2007 (31.05.2007) PCT WO 2007/061529 Al (51) International Patent Classification: GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, A61K 9/14 (2006.01) KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, (21) International Application Number: NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, PCT/US2006/040197 SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (22) International Filing Date: 13 October 2006 (13.10.2006) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (26) Publication Language: English ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,MC, NL, PL, PT, (30) Priority Data: RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, 11/282,507 18 November 2005 (18.1 1.2005) US GN, GQ, GW, ML, MR, NE, SN, TD, TG). (71) Applicant (for all designated States except US): SCI- Declarations under Rule 4.17: DOSE PHARMA INC.
    [Show full text]